Zydus Lifesciences zooms 4% after getting USFDA nod for Dapagliflozin Tablets, 5 mg & 10 mgZydus Lifesciences zooms 4% after getting USFDA nod for Dapagliflozin Tablets, 5 mg & 10 mg

Introduction

Leading pharmaceutical company receives USFDA approval for Dapagliflozin tablets 5 mg and 10 mg, secures 180 days shared exclusivity, targets USD 10.2 billion market in United States.

Also Read: Texmaco Rail share price soars on bagging ₹39.26 Cr Southern Railway electrification order

Share price movement of Zydus Lifesciences

On April 08, 2026, Zydus Lifesciences Ltd opened at ₹910.80, up 4.25% from its previous close of ₹873.65. The stock reached a high of ₹910.80 (4.25%) and a low of ₹879.90. By 10:40 AM, it traded at ₹885.40, a 1.34% increase, with a market cap of ₹89,091.96 crore.

Zydus Gets USFDA Nod for Dapagliflozin

Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration for Dapagliflozin tablets in 5 mg and 10 mg strengths, reference listed drug Farxiga tablets.

Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor used with diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus, according to the company filing official regulatory.

Zydus will manufacture the tablets at its SEZ Ahmedabad facility and gains 180 days shared generic exclusivity, while United States sales of Dapagliflozin tablets stood at approximately USD 10.2 billion.

Stock performance of Zydus Lifesciences for period of 1 week, 6 months, and 1 year

Zydus Lifesciences Ltd delivered a 1-week return of 1.19%, a 6-month return of -12.1%, and a 1-year return of 1.68%.

Also Read: Deep Industries jumps 9% after winning ONGC contract worth ₹59 Cr

Shareholding pattern of Zydus Lifesciences

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	75.00%	75.00%	75.00%
FII	7.10%	7.30%	7.10%
DII	11.10%	10.90%	11.10%
Public	6.90%	6.80%	6.70%

About Zydus Lifesciences

Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) formed in 1995 after restructuring. The company focuses on healthcare innovation, with turnover exceeding Rs. 14,253 crores in FY20.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs